These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 7028619

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of guanfacine on growth hormone, prolactin, renin, lipoproteins and glucose in essential hypertension.
    Hauger-Klevene JH, Balossi EC, Scornavacchi JC.
    Am J Cardiol; 1986 Mar 28; 57(9):27E-31E. PubMed ID: 3513527
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL, Strocchi E, Ambrosioni E, Magnani B.
    Int J Clin Pharmacol Res; 1983 Mar 28; 3(1):35-9. PubMed ID: 6384071
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hemodynamic effects of guanfacine in essential hypertension.
    Feldstein CA, Cohen AA, Sabaris RP, Burucúa JE.
    Clin Ther; 1984 Mar 28; 6(3):325-34. PubMed ID: 6373009
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Hypotensive and hemodynamic effects of guanfacine in arterial hypertension].
    Erina EV, Beliakova EV, Charyev KhZ, Panfilov VV.
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1989 Mar 28; 12(1):63-7. PubMed ID: 2663029
    [Abstract] [Full Text] [Related]

  • 15. Low dose guanfacine and methyldopa in mild essential hypertension. A multiple centre study.
    Viskoper RJ, Laszt A, Paran E, Ben Ari J, Goren Y, Modan M.
    Neth J Med; 1987 Aug 28; 31(1-2):58-65. PubMed ID: 3309693
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS, Farsky K, Bouchard S, Lalonde Y, Brookman S.
    Clin Ther; 1985 Aug 28; 7(2):199-204. PubMed ID: 3886142
    [Abstract] [Full Text] [Related]

  • 18. A multicenter, randomized, double-blind dose-response evaluation of step-2 guanfacine versus placebo in mild to moderate hypertension.
    Materson BJ, Kessler WB, Alderman MH, Canosa FL, Finnerty FA, Savran SV, McMillen JI, Marlon AM.
    Am J Cardiol; 1986 Mar 28; 57(9):32E-37E. PubMed ID: 3513528
    [Abstract] [Full Text] [Related]

  • 19. Guanfacine in the treatment of hypertensives with a pronounced response to exercise and diabetes mellitus.
    Dvorák I, Podrouzková B, Kocourková J, Kubesová H, Spác J, Nĕmcová H, Blaha M.
    Cor Vasa; 1987 Mar 28; 29(4 Suppl 1):30-6. PubMed ID: 3315448
    [Abstract] [Full Text] [Related]

  • 20. [A new antihypertensive agent used in a clinical setting].
    Wetzels E, Raschig A, Kaiser HJ.
    Med Klin; 1980 Sep 12; 75(19):688-92. PubMed ID: 7001207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.